Previous 10 | Next 10 |
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock defied the market's gravity on Wednesday by rising incrementally. Although it was a challenging day for stocks in general, with the S&P 500 index sinking by over 1%, BioCryst landed in the black thanks to some encouraging regulat...
Commercial-stage biotech BioCryst Pharmaceuticals (NASDAQ:BCRX) announced on Wednesday that the FDA granted its Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP). FOP is characteriz...
RESEARCH TRIANGLE PARK, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients w...
Swissmedic granted marketing authorization to BioCryst Pharmaceuticals' (NASDAQ:BCRX) once-daily oral drug Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older. HAE is a disorder characterized by recurrent epis...
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the routine prevention of recurrent heredita...
Health Canada approved BioCryst Pharmaceuticals' (NASDAQ:BCRX) once-daily oral drug Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older. HAE is a disorder characterized by recurrent episodes (attacks) of...
RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO ® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) atta...
BioCryst Pharmaceuticals (NASDAQ: BCRX) had a Thursday to forget, at least as far as its stock was concerned. The company's shares took an almost 4% tumble that day, due to first-quarter results that investors clearly considered inadequate. For the quarter, BioCryst booked $49.9...
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q1 2022 Earnings Call May 05, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q1 2022 Earnings Call Transcript ...
Call Start: 08:30 Call End: 09:24 BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2022 Earnings Conference Call May 5, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Dr. Bill She...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...